

South Alabama Medical Science Foundation
Cash Receipts (for Projects over \$2,000 only)
October 1, 2019 - September 30, 2020

<u>Dept</u>	<u>Project Number</u>	<u>Project Title</u>	<u>Responsible Person</u>	<u>Source of Funding</u>	<u>19-20 Receipts</u>
<u>Emergency Medicine</u>					
	63882	Gloria-AF: Global Registry on Long-term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation	Dr Panacek, E	Inflammatix, Inc	4,550.00
Total Emergency Medicine					\$ 4,550.00
<u>Internal Medicine</u>					
	63697	Gloria-AF: Global Registry on Long-term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation	Dr Cohen, M	Boehringer Ingelheim Pharmaceuticals	2,661.52
	63842	A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer (Ferric Carboxymaltose) as Treatment for Heart Failure with Iron Deficiency (HEART-FID)	Dr Malozzi, C	Luitpold Pharmaceuticals	19,264.00
	63847	A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome	Dr Malozzi, C	CSL Behring, LLC	2,783.00
	63866	Benefits of uCor in Ambulatory Decompensated Heart Failure (BMAD HF)	Dr Rahimi, F	Zoll Services, LLC	8,450.00
Total Internal Medicine					\$ 33,158.52

South Alabama Medical Science Foundation
 Cash Receipts (for Projects over \$2,000 only)
 October 1, 2019 - September 30, 2020

<u>Dent</u>	<u>Project Number</u>	<u>Project Title</u>	<u>Responsible Person</u>	<u>Source of Funding</u>	<u>19-20 Receipts</u>
<u>Microbiology</u>					
	63883	Evaluation of Nanoparticle Formulations of Antiviral Drugs Against SARS-CoV-2 Virus	Dr Rayner, J	Hillstream Bio	9,000.00
	63884	Aqua Resources Kill Curve for SARS-CoV-2 Virus	Dr Kim, J	Aqua Resources	5,000.00
				Total Microbiology	\$ 14,000.00

South Alabama Medical Science Foundation
Cash Receipts (for Projects over \$2,000 only)
October 1, 2019 - September 30, 2020

<u>Dept</u>	<u>Project Number</u>	<u>Project Title</u>	<u>Responsible Person</u>	<u>Source of Funding</u>	<u>19-20 Receipts</u>
<u>Neurology</u>					
	63814	A Phase 1B/2, Multi-Center, Double-Blind (Principal Investigators and Study Subjects Blinded, Sponsor Unblinded), Placebo-Controlled, Randomized Single-Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040B in Subjects with Acute Ischemic Stroke	Dr Cordina, S	Daichi Sankyo	11,928.21
	63785	Long-Term, Prospective, Multinational, Parallel-Cohort Study Monitoring Safety in Patients with MS Newly Started with Fingolimod Once Daily or Treated with Another Approved Disease-Modifying Therapy	Dr Minto, E	Novartis	16,358.10
	63868	Cladribine tablets: Observational Evaluation of Effectiveness and Patient Reported Outcomes in Suboptimally Controlled Patients Previously Taking Injectable Disease-Modifying Drugs for Relapsing Forms of Multiple Sclerosis	Dr Kilgo, W	EMD Serono Research & Development	2,314.00
	63874	Cladribine Tablets: Observational Evaluation of Effectiveness and Patient-Reported Outcomes (PROs) in Suboptimally Controlled Patients Previously Taking Oral Disease Modifying Drugs (DMDs) for Relapsing forms of Multiple Sclerosis (RMS) (Master-2)	Dr Kilgo, W	EMD Serono Research & Development	9,945.00
	63867	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Epilepsy	Dr Naritoku, D	Xenon Pharmaceuticals	6,986.75
				Total Neurology	47,532.06

South Alabama Medical Science Foundation
 Cash Receipts (for Projects over \$2,000 only)
 October 1, 2019 - September 30, 2020

<u>Dent</u>	<u>Project Number</u>	<u>Project Title</u>	<u>Responsible Person</u>	<u>Source of Funding</u>	<u>19-20 Receipts</u>
<u>OBGYN</u>					
	63719	SQNM-T21-107 - Collection of Whole Blood Specimen from Pregnant Women at Increased Risk for Fetal Chromosomal Abnormality for Use in Development of a Noninvasive Prenatal Test in the Detection of the Relative Quantity of Chromosomal Material in Circulating Cell-Free DNA Extracted from Maternal Plasma	Dr Baker, S	Sequenom	10,125.00
	63813	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of DigiFab in Antepartum Subjects with Severe Preeclampsia	Dr Brocato, B	Velo Bio, LLC	12,000.00
				Total OBGYN	\$ 22,125.00
<u>Pediatrics</u>					
	63876	Effects of an Exclusive Human Milk Diet on Enteral Feeding Outcomes of Neonates with Congenital Gastrointestinal Disorders	Dr Eyal, F	Prolacta Bioscience, Inc	10,400.00
	63748	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects with Sickle Cell Disease	Dr Imran, H	Pfizer	3,664.16
	63869	HEM-POWR: Observational Study Evaluating Effectiveness and Safety of Real-World Treatment with Damoctocog Alfa Pegol in Previously Treated Patients with Hemophilia A	Dr Marri, P	Bayer HEM-POWR	9,906.00
				Total Pediatrics	\$ 23,970.16

South Alabama Medical Science Foundation
Cash Receipts (for Projects over \$2,000 only)
October 1, 2019 - September 30, 2020

<u>Dept</u>	<u>Project Number</u>	<u>Project Title</u>	<u>Responsible Person</u>	<u>Source of Funding</u>	<u>19-20 Receipts</u>
<u>Sickle Cell</u>					
	63823	A Phase 3, Double-Blind, Randomized, Placeo-Controlled, Multicenter Study of GBT440 Administered Orally to Patients with Sickle Cell Disease	Dr Haynes Jr, J	Global Blood Therapeutics	5,360.70
	63873	An Open-Label, Expanded Access Protocol for Patients with Sickle Cell Disease Who Have No Alternative Treatment Outcomes	Dr Haynes Jr, J	Global Blood Therapeutics	17,530.10
				Total Sickle Cell	\$ 17,530.10
<u>Surgery</u>					
	63855	A Multicenter, Open-Label, Sponsor-Blinded, Randomized, Active-Controlled, Parallel Group, Pivotal Study to Evaluate the Efficacy, Safety, and Tolerability of Murepavadin Given with Ertapenem Versus an Anti-Pseudomonal -B-Lactam Based Antibiotic in Adults with Nosocomial Pneumonia Suspected or Confirmed to be Due to Pseudomonas Aeruginosa	Dr Brevard, S	Polyphor, Ltd	5,026.45
	63879	Expanded Access Treatment Protocol: Use of Nexobrid for Treatment of Acute Deep Partial and Full Thickness Burn Injuries Protocol MW2018-06-21	Dr Bright, A	Mediwound	11,700.00
	63857	A Randomized, Double-Blind, Placebo-Controlled, Phase2 Dose Ranging Study to Evaluate the Efficacy and Safety of 2 Dose Regimens of Intravenous TAK-954 for the Prophylaxis and Treatment of Postoperative Gastrointestinal Dysfunction in Patients Undergoing Large and Small-Bowel Resection	Dr Rider, P	Millenium Pharmaceuticals/Takeda	24,979.86
				Total Surgery	\$ 41,706.31

South Alabama Medical Science Foundation
Cash Receipts (for Projects over \$2,000 only)
October 1, 2019 - September 30, 2020

<u>Dept</u>	<u>Project Number</u>	<u>Project Title</u>	<u>Responsible Person</u>	<u>Source of Funding</u>	<u>19-20 Receipts</u>
<u>USAMCI</u>					
	63787	Safety and Effectiveness of Ramucirumab in Patients with Advanced Gastric Cancer in the European Union and North America: A Prospective Observational Registry (I4T-MC-JVDD)	Dr Khushman, M	Eli Lilly	11,953.00
	63721	A Multicenter, Multinational, Phase II Study to Evaluate Pertuzumab in Combination with Trastuzumab and Standard Neoadjuvant Anthracycline-Based Chemotherapy in Patients with HER2-Positive, Locally Advanced, Inflammatory, or Early-Stage Breast Cancer	Dr Norden, C	Genentech Inc	5,833.80
	63799	A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer	Dr Norden, C	Alliance Foundation/Pfizer	9,800.00
	63800	Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma	Dr Norden, C	Cascadian Therapeutics	66,721.00
	63755	A Phase I, Open-Label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSF0010718C in Subjects with Metastatic or Locally Advanced Tumors and Expansion to Selected Indications	Dr Rocconi, R	EMD Serono	3,672.00
	63778	A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma	Dr Taylor, W	Halozyme, Inc	21,988.70
				Total USAMCI	\$ 119,968.50
				Total All Departments	\$ 324,540.65